Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-blind, Placebo-controlled Multicenter Phase II Trial to Evaluate the Efficacy and Safety of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Subjects With Relapsed Ovarian Cancer (2nd or Further Line)

NCT03622931 is registered in ClinicalTrials.gov with Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH as lead sponsor.

NCT NCT03622931
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03622931 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-blind, Placebo-controlled Multicenter Phase II Trial to Evaluate the Efficacy and Safety of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Subjects With Relapsed Ovarian Cancer (2nd or Further Line)
Lead sponsor
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Phase
Phase 2
Overall status
Terminated
Start date
February 1, 2014
Completion date
January 17, 2019
Enrollment
21 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer